ArticleBiological procedures online2025
Commentary on: Isolation and Quantification of Blood Apoptotic Bodies, a Non-invasive Tool to Evaluate Apoptosis in Patients with Ischemic Stroke and Neurodegenerative Diseases.
Article in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembrane-bound vesicles called apoptotic bodies (ApoBDs) formed during apoptosis are being recognized as non-invasive biomarkers for neurological diseases like dementia and ischemic stroke. Centrifugation-based isolation of these vesicles from blood was suggested in a recent paper by Serrano-Heras et al. (2020), which asserted their use for clinical diagnosis. This initial study provides a foundational methodology for ApoBD diagnostics. Albeit, centrifugation parameters employed present technical challenges that require optimization to ensure the purity and reproducibility of ApoBD preparations for clinical utility.
resultsDue to the use of improper centrifugation speeds (160×g and 700×g) not consistent with accepted norms for the separation of platelets (ideally 2,000-5,000×g), running the risk of being seriously contaminated by platelets and platelet-derived EVs (P-EVs), which make up 70-90% of EVs in circulation. Such contamination can render functional studies problematic, cloud proteomic and size-distribution analysis, and lower the specificity of ApoBDs enumeration on the basis of Annexin V/PI labeling. Even more extreme centrifugation has little chance to eliminate platelets completely, according to comparative literature data. Increased centrifugal pressure, density gradient separation, size-exclusion chromatography (SEC), and confirmation with platelet-specific markers are among some procedural changes recommended to improve sample purity in attempts to solve such problems.
conclusionsEven as the Serrano-Heras et al. study pinpoints the potential of ApoBDs as biomarkers, constraints to the procedure under consideration pose the threat of bias in future studies. Proper isolation of ApoBDs requires multimodal confirmation, optimized platelet removal protocols and clinically feasible methods like SEC are essential to enhance ApoBDs isolation for neurological disease diagnostics. Rectification of such issues enhance significantly the practicality of ApoBDs in clinical practice for the detection of neurological illnesses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.